Pfizer has begun a study comparing its original COVID-19 vaccine with doses specially tweaked to match the omicron variant.
COVID-19 vaccine-makers have been updating their shots to better match omicron in case global health authorities decide the change is needed.
The original vaccines still offer good protection against severe illness and death. Studies in the U.S. and elsewhere have made clear that adding a booster dose strengthens that protection and improves the chances of avoiding a milder infection. Full study results will take many months as volunteers receive multiple vaccine doses — and as researchers measure how long virus-fighting antibodies remain at high levels after an omicron-adapted dose versus the regular booster.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Covid-19 news: Strain on health services led to extra non-covid deathsToday’s covid-19 news: · 4000 excess non-covid 19 deaths occurred in England during first year of pandemic · Acute phase of pandemic could end in 2022 with improved vaccination rates, says WHO · Israel recommends fourth vaccine dose for all adults
Consulte Mais informação »
Pfizer says it's starting clinical studies of an omicron-based COVID-19 vaccinePfizer and BioNTech said Tuesday they've stated clinical trials for an omicron-based COVID-19 vaccine.
Consulte Mais informação »
France’s New COVID-19 Vaccine Pass Begins MondayFrance’s new COVID-19 vaccine pass goes into effect on Monday, requiring ages 16 and older to show proof of vaccination to enter public places such as bars, restaurants, sports events, theaters, museums, entertainment venues and domestic flights and trains.
Consulte Mais informação »
Pfizer Begins Clinical Trial for Omicron-Specific COVID VaccinePfizer has begun a study comparing its original COVID-19 vaccine with doses specially tweaked to match the omicron variant
Consulte Mais informação »